D Alan Anthoney
Overview
Explore the profile of D Alan Anthoney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
West E, Sadoun A, Bendjama K, Erbs P, Smolenschi C, Cassier P, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39785814
Background: Effective treatment for patients with metastatic cancer is limited, particularly for colorectal cancer patients with metastatic liver lesions (mCRC), where accessibility to numerous tumours is essential for favourable clinical...
2.
West E, Scott K, Tidswell E, Bendjama K, Stojkowitz N, Lusky M, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565310
is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable immune consequences to...
3.
Thomas A, Virdee P, Eatock M, Lord S, Falk S, Anthoney D, et al.
Eur J Cancer
. 2019 Nov;
124:131-141.
PMID: 31765988
Background: AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently...
4.
Cook N, Basu B, Smith D, Gopinathan A, Evans J, Steward W, et al.
Br J Cancer
. 2018 Feb;
118(6):793-801.
PMID: 29438372
Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine....
5.
Samson A, Scott K, Taggart D, West E, Wilson E, Nuovo G, et al.
Sci Transl Med
. 2018 Jan;
10(422).
PMID: 29298869
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined by tumor...
6.
Propper D, Jones K, Anthoney D, Mansoor W, Ford D, Eatock M, et al.
BMC Cancer
. 2016 Oct;
16(1):779.
PMID: 27724887
Background: TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in...
7.
Valle J, Wasan H, Lopes A, Backen A, Palmer D, Morris K, et al.
Lancet Oncol
. 2015 Jul;
16(8):967-78.
PMID: 26179201
Background: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed...
8.
Anthoney D, Naik J, Macpherson I, Crawford D, Hartley J, Hartley J, et al.
BMC Cancer
. 2012 Nov;
12:536.
PMID: 23170896
Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of...
9.
Massard C, Soria J, Anthoney D, Proctor A, Scaburri A, Pacciarini M, et al.
Cell Cycle
. 2011 Mar;
10(6):963-70.
PMID: 21368575
Background: PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. The primary objectives of this first in man study were to determine...
10.
Kirwan I, Loadman P, Swaine D, Anthoney D, Pettit G, Lippert 3rd J, et al.
Clin Cancer Res
. 2004 Feb;
10(4):1446-53.
PMID: 14977848
Purpose: Combretastatin A4 phosphate (CA4P) and its structural analog, combretastatin A1 phosphate (CA1P), are soluble prodrugs capable of interacting with tubulin and causing rapid vascular shutdown within tumors. CA4P has...